Developer docs
API playgroundTry for free, no card

Search company profiles

ExCEEd Orphan

Full company profile

uuid000p88i

Namestring
ExCEEd Orphan
Legal namestring
ExCEEd Orphan s.r.o.
Company typeenum
Private
Founded yearint
2018
Short descriptiontext

ExCEEd Orphan is a private specialty pharmaceutical services company that supports rare disease drug manufacturers with distribution, market access, and pharmacovigilance services across Central and Eastern Europe, operating through entities in Croatia and the Czech Republic.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPrague, Czechia
HQ citystring
Prague
HQ countrystring
Czechia
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orphan drug distribution, rare disease pharmaceuticals, pharmacovigilance services, drug safety services, Central Eastern Europe
Industry1 code
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Orphan Drug Distribution & Pharmacovigilance Services
No data
Cost components4 values
Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ExCEEd Orphan performs multiple successful launches of rare disease medications (orphan drugs) in Central & Eastern European countries. The company provides specialized regional distribution and pharmacovigilance / drug safety services to support orphan drug commercialization across the CEE region, acting as a niche market-entry and lifecycle partner for pharmaceutical manufacturers of rare disease therapies.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Orphan Drug Launch & Distribution Services (CEE)
No data
Peers10 records
TypeDirect peer
Description

Global orphan and rare-disease specialist with established CEE commercial infrastructure, competing for the same sponsor mandates and distribution rights that ExCEEd Orphan targets.

TypeDirect peer
Description

Specialty division of Recordati focused on orphan drugs across Europe; directly competes with ExCEEd Orphan for CEE distribution agreements and licensing partnerships.

TypeBroad incumbent
Description

Large rare-disease biopharma with its own CEE commercialization apparatus; competes as a sponsor who may or may not outsource CEE launches to specialists like ExCEEd Orphan.

TypeBroad incumbent
Description

Rare-disease unit of AstraZeneca operating broadly in the same therapeutic categories; potential sponsor partner but also a competitor that may internalize CEE distribution.

TypeEmerging player
Description

Emerging rare-disease biotech that has historically used regional partners for European commercialization; representative of the sponsor customer type ExCEEd Orphan serves.

TypeRegional player
Description

One of the largest CEE-headquartered pharmaceutical manufacturers with broad regional reach; competes for CEE pharma services and distribution mandates across therapeutic areas including rare diseases.

TypeRegional player
Description

Prague-headquartered pan-European generics and specialty pharma company with strong CEE presence; overlaps with ExCEEd Orphan on regional pharma distribution and market-access services.

TypeRegional player
Description

Hungary-headquartered mid-cap pharma with deep CEE distribution footprint and growing specialty/rare-disease exposure; relevant comparable for CEE-centric pharma distribution scale.

TypeRegional player
Description

CEE-focused pharmaceutical company with broad portfolio across CEE markets; provides a comparable for regional pharma distribution and market-access operations.

TypeEmerging player
Description

European specialty/CDMO pharma with rare-disease exposure; comparable in scale and regional focus to ExCEEd Orphan and a potential adjacent competitor for niche CEE pharma mandates.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ExCEEd Orphan

Orphan Drug Distribution & Pharmacovigilance Servicesexceedorphan.com

ExCEEd Orphan is a private specialty pharmaceutical services company that supports rare disease drug manufacturers with distribution, market access, and pharmacovigilance services across Central and Eastern Europe, operating through entities in Croatia and the Czech Republic.

ExCEEd Orphan firmographics

Firmographics
Name
ExCEEd Orphan
Legal name
ExCEEd Orphan s.r.o.
Website
https://exceedorphan.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
ExCEEd Orphan is a private specialty pharmaceutical services company that supports rare disease drug manufacturers with distribution, market access, and pharmacovigilance services across Central and Eastern Europe, operating through entities in Croatia and the Czech Republic.
Ownership category
akta.pro rank

ExCEEd Orphan industry classification

Industry
Product category
Orphan Drug Distribution & Pharmacovigilance Services
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Orphan drug distribution
  • Rare disease pharmaceuticals
  • Pharmacovigilance services
  • Drug safety services
  • Central Eastern Europe

Where ExCEEd Orphan is headquartered

Location

Headquarters

HQ city
Prague
HQ country
Czechia
HQ region
Europe

Offices1 record

Markets served

ExCEEd Orphan business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Marketing or Sales

ExCEEd Orphan product offering

Product offering

Core offering

ExCEEd Orphan performs multiple successful launches of rare disease medications (orphan drugs) in Central & Eastern European countries. The company provides specialized regional distribution and pharmacovigilance / drug safety services to support orphan drug commercialization across the CEE region, acting as a niche market-entry and lifecycle partner for pharmaceutical manufacturers of rare disease therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Orphan Drug Launch & Distribution Services (CEE)

Companies that use ExCEEd Orphan

Customer profile

Ideal customer profiles1 record

ExCEEd Orphan technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

ExCEEd Orphan competitors and assessment

Company assessment

Direct peers

  • Swedish Orphan Biovitrum (SOBI): Global orphan and rare-disease specialist with established CEE commercial infrastructure, competing for the same sponsor mandates and distribution rights that ExCEEd Orphan targets.
  • Recordati Rare Diseases (Orphan Europe): Specialty division of Recordati focused on orphan drugs across Europe; directly competes with ExCEEd Orphan for CEE distribution agreements and licensing partnerships.

Broad incumbents

  • BioMarin Pharmaceutical: Large rare-disease biopharma with its own CEE commercialization apparatus; competes as a sponsor who may or may not outsource CEE launches to specialists like ExCEEd Orphan.
  • Alexion (AstraZeneca Rare Disease): Rare-disease unit of AstraZeneca operating broadly in the same therapeutic categories; potential sponsor partner but also a competitor that may internalize CEE distribution.

Emerging players

  • Ultragenyx Pharmaceutical: Emerging rare-disease biotech that has historically used regional partners for European commercialization; representative of the sponsor customer type ExCEEd Orphan serves.
  • Dipharma: European specialty/CDMO pharma with rare-disease exposure; comparable in scale and regional focus to ExCEEd Orphan and a potential adjacent competitor for niche CEE pharma mandates.

Regional players

  • Polpharma: One of the largest CEE-headquartered pharmaceutical manufacturers with broad regional reach; competes for CEE pharma services and distribution mandates across therapeutic areas including rare diseases.
  • Zentiva: Prague-headquartered pan-European generics and specialty pharma company with strong CEE presence; overlaps with ExCEEd Orphan on regional pharma distribution and market-access services.
  • Gedeon Richter: Hungary-headquartered mid-cap pharma with deep CEE distribution footprint and growing specialty/rare-disease exposure; relevant comparable for CEE-centric pharma distribution scale.
  • Egis Pharmaceuticals: CEE-focused pharmaceutical company with broad portfolio across CEE markets; provides a comparable for regional pharma distribution and market-access operations.

Market position

Customer concentration

ExCEEd Orphan financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ExCEEd Orphan leadership team

Management profile

Number of profiles

ExCEEd Orphan funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ExCEEd Orphan M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ExCEEd Orphan

What does ExCEEd Orphan do?

ExCEEd Orphan performs multiple successful launches of rare disease medications (orphan drugs) in Central & Eastern European countries. The company provides specialized regional distribution and pharmacovigilance / drug safety services to support orphan drug commercialization across the CEE region, acting as a niche market-entry and lifecycle partner for pharmaceutical manufacturers of rare disease therapies.

Is ExCEEd Orphan a public or private company?

ExCEEd Orphan is a private company. It is classified as unknown and is currently operating.

When was ExCEEd Orphan founded?

ExCEEd Orphan was founded in 2018. It employs 11 to 50 people.

Where is ExCEEd Orphan based?

ExCEEd Orphan is headquartered in Prague, Czechia, in the Europe region.

Who are ExCEEd Orphan's main competitors?

Direct peers on record are Swedish Orphan Biovitrum (SOBI) and Recordati Rare Diseases (Orphan Europe). Broad incumbents are BioMarin Pharmaceutical and Alexion (AstraZeneca Rare Disease). Emerging players are Ultragenyx Pharmaceutical and Dipharma. Regional players are Polpharma, Zentiva, Gedeon Richter and Egis Pharmaceuticals.

Does ExCEEd Orphan have an API?

No public API is recorded for ExCEEd Orphan.

What industry is ExCEEd Orphan in?

ExCEEd Orphan's product category is Orphan Drug Distribution & Pharmacovigilance Services. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals